JP2017503842A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017503842A5 JP2017503842A5 JP2016548172A JP2016548172A JP2017503842A5 JP 2017503842 A5 JP2017503842 A5 JP 2017503842A5 JP 2016548172 A JP2016548172 A JP 2016548172A JP 2016548172 A JP2016548172 A JP 2016548172A JP 2017503842 A5 JP2017503842 A5 JP 2017503842A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- cell lymphoma
- therapeutic agent
- hodgkin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461931078P | 2014-01-24 | 2014-01-24 | |
| US201461931075P | 2014-01-24 | 2014-01-24 | |
| US61/931,075 | 2014-01-24 | ||
| US61/931,078 | 2014-01-24 | ||
| US201462077127P | 2014-11-07 | 2014-11-07 | |
| US62/077,127 | 2014-11-07 | ||
| PCT/US2015/012733 WO2015112888A1 (en) | 2014-01-24 | 2015-01-23 | Apilimod compositions and methods for using same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020201440A Division JP2021046430A (ja) | 2014-01-24 | 2020-12-04 | 癌治療のためのアピリモド（ａｐｉｌｉｍｏｄ）組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017503842A JP2017503842A (ja) | 2017-02-02 |
| JP2017503842A5 true JP2017503842A5 (https=) | 2018-03-08 |
| JP6855243B2 JP6855243B2 (ja) | 2021-04-07 |
Family
ID=53681989
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016548172A Expired - Fee Related JP6855243B2 (ja) | 2014-01-24 | 2015-01-23 | 癌治療のためのアピリモド（ａｐｉｌｉｍｏｄ）組成物 |
| JP2020201440A Pending JP2021046430A (ja) | 2014-01-24 | 2020-12-04 | 癌治療のためのアピリモド（ａｐｉｌｉｍｏｄ）組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020201440A Pending JP2021046430A (ja) | 2014-01-24 | 2020-12-04 | 癌治療のためのアピリモド（ａｐｉｌｉｍｏｄ）組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US10179135B2 (https=) |
| EP (1) | EP3096757B1 (https=) |
| JP (2) | JP6855243B2 (https=) |
| KR (1) | KR102320190B1 (https=) |
| CN (1) | CN106659716B (https=) |
| AU (1) | AU2015209133B2 (https=) |
| BR (1) | BR112016017112A2 (https=) |
| CA (1) | CA2937655C (https=) |
| IL (1) | IL246879B (https=) |
| MX (1) | MX373818B (https=) |
| RU (2) | RU2019107011A (https=) |
| WO (1) | WO2015112888A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102320190B1 (ko) | 2014-01-24 | 2021-11-03 | 에이아이 테라퓨틱스, 인코포레이티드 | 아필리모드 조성물 및 이를 사용하기 위한 방법 |
| RU2739992C2 (ru) * | 2014-11-07 | 2020-12-30 | ЭйАй ТЕРАПЬЮТИКС, ИНК. | Композиции апилимода и способы их применения в лечении колоректального рака |
| CA2966359A1 (en) | 2014-11-07 | 2016-05-12 | Lam Therapeutics, Inc. | Apilimod for use in the treatment of renal cancer |
| WO2016118709A1 (en) * | 2015-01-23 | 2016-07-28 | Lam Therapeutics, Inc. | Anti-viral compositions containing pikfyve inhibitors and use thereof |
| US20180078561A1 (en) * | 2015-03-31 | 2018-03-22 | Lam Therapeutics, Inc. | Active metabolites of apilimod and uses thereof |
| TWI746449B (zh) * | 2015-07-20 | 2021-11-21 | 美商Ａｉ治療公司 | 使用阿吡莫德治療癌症之方法 |
| WO2017127661A1 (en) * | 2016-01-21 | 2017-07-27 | Lam Therapeutics, Inc. | Biomarkers for treating cancer with apilimod |
| KR20180015441A (ko) | 2016-08-03 | 2018-02-13 | 엘지전자 주식회사 | 롤리 키보드 |
| RU2019108279A (ru) * | 2016-08-25 | 2020-09-25 | ЭйАй ТЕРАПЬЮТИКС, ИНК. | Композиции, содержащие ингибиторы pikfyve, и способы, связанные с ингибированием сигнального пути rank |
| US12589097B2 (en) | 2018-02-21 | 2026-03-31 | OrphAl Therapeutics Inc. | Apilimod compositions and methods of use |
| TW202000205A (zh) | 2018-02-21 | 2020-01-01 | 美商Ａｉ治療公司 | 使用阿吡莫德與麩胺酸性劑的組合治療 |
| CN108743947B (zh) * | 2018-07-04 | 2020-12-15 | 复旦大学附属肿瘤医院 | 一种治疗b细胞淋巴瘤的药物组合物 |
| CN110496128B (zh) * | 2019-09-23 | 2022-09-30 | 吉林大学 | 利培酮或帕潘立酮在制备治疗弥漫性大b细胞淋巴瘤的药物中的应用 |
| TWI885039B (zh) | 2020-01-13 | 2025-06-01 | 美商邊際分析公司 | 經取代吡唑并嘧啶及其用途 |
| IL309143A (en) * | 2021-06-11 | 2024-02-01 | Orphai Therapeutics Inc | Stabilized apilimod compositions and uses thereof |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5210015A (en) | 1990-08-06 | 1993-05-11 | Hoffman-La Roche Inc. | Homogeneous assay system using the nuclease activity of a nucleic acid polymerase |
| DK1921169T3 (da) | 1993-11-12 | 2012-06-04 | Phri Properties Inc | Hybridiseringssonder til nukleinsyredetektion, universelle stamceller, fremgangsmåder og kits |
| US6693097B2 (en) | 2001-11-30 | 2004-02-17 | Synta Pharmaceuticals Corp. | Pyrimidine compounds |
| NZ584288A (en) | 2004-02-06 | 2011-10-28 | Elan Pharm Inc | Methods and compositions for treating tumors and metastatic disease |
| TWI380816B (zh) | 2004-04-13 | 2013-01-01 | Synta Pharmaceuticals Corp | 抑制介白素-１２（ｉｌ-１２）生成之二鹽抑制劑 |
| JP2008512490A (ja) * | 2004-09-08 | 2008-04-24 | チェルシー・セラピューティクス，インコーポレイテッド | 異常細胞増殖および炎症の障害を治療するための代謝的に不活性な葉酸拮抗剤 |
| US7923557B2 (en) | 2004-11-10 | 2011-04-12 | Synta Pharmaceuticals Corporation | Process for preparing trisubstituted pyrimidine compounds |
| WO2006124662A1 (en) | 2005-05-13 | 2006-11-23 | Synta Pharmaceuticals Corp. | Il-12 modulatory compounds |
| WO2006128129A2 (en) * | 2005-05-26 | 2006-11-30 | Synta Pharmaceuticals Corp. | Method for treating cancer |
| ES2365869T3 (es) | 2005-11-17 | 2011-10-11 | OSI Pharmaceuticals, LLC | COMPUESTOS BICÍCLICOS FUSIONADOS INHIBIDORES DE LA mTOR. |
| AR057960A1 (es) | 2005-12-02 | 2007-12-26 | Osi Pharm Inc | Inhibidores de proteina quinasa biciclicos |
| TW200738725A (en) | 2006-01-25 | 2007-10-16 | Osi Pharm Inc | Unsaturated mTOR inhibitors |
| MX2009000385A (es) | 2006-07-12 | 2009-04-06 | Univ Tennessee Res Foundation | Acil-anilidas sustituidas y metodos de uso de las mismas. |
| WO2008098058A1 (en) | 2007-02-06 | 2008-08-14 | Novartis Ag | Pi 3-kinase inhibitors and methods of their use |
| RU2438664C2 (ru) | 2007-05-15 | 2012-01-10 | Пирамал Лайф Сайнсиз Лимитед | Синергическая фармацевтическая комбинация для лечения рака |
| DE102007036076A1 (de) | 2007-08-01 | 2009-02-05 | Bayer Healthcare Aktiengesellschaft | Dipeptoid-Produgs und ihre Verwendung |
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| JP5258331B2 (ja) * | 2008-03-03 | 2013-08-07 | ロート製薬株式会社 | 光安定性が改善されたニューキノロン系抗菌剤含有医薬組成物 |
| US20110224223A1 (en) | 2008-07-08 | 2011-09-15 | The Regents Of The University Of California, A California Corporation | MTOR Modulators and Uses Thereof |
| EP2318406B1 (en) | 2008-07-17 | 2016-01-27 | Critical Outcome Technologies, Inc. | Thiosemicarbazone inhibitor compounds and cancer treatment methods |
| AU2011224457B2 (en) * | 2010-03-08 | 2014-11-06 | Sloan-Kettering Institute For Cancer Research | Cdc7 kinase inhibitors and uses thereof |
| ES2768349T3 (es) | 2010-03-29 | 2020-06-22 | Ea Pharma Co Ltd | Preparación farmacéutica que comprende un derivado de fenilalanina |
| US8402515B2 (en) | 2010-05-06 | 2013-03-19 | Jonathan Weizman | Apparatus and method for establishing a peer-to-peer communication session with a client device |
| WO2011146727A1 (en) * | 2010-05-19 | 2011-11-24 | Philip Bosch | Methods of treating interstitial cystitis |
| US8709419B2 (en) | 2010-08-17 | 2014-04-29 | Hoffmann-La Roche, Inc. | Combination therapy |
| JP6061346B2 (ja) * | 2010-11-19 | 2017-01-18 | エコール ポリテクニーク フェデラル ドゥ ローザンヌ （イーピーエフエル） | ２−ピペラジン−１−イル−４ｈ−１，３−ベンゾチアジン−４−オン誘導体、および哺乳類の感染症治療へのその使用 |
| WO2013152342A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Anti-cancer mtor inhibitor and anti-androgen combination |
| US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| HK1203971A1 (en) | 2012-05-15 | 2015-11-06 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| EP2903644A4 (en) | 2012-10-05 | 2016-03-09 | Cerulean Pharma Inc | TREATMENT OF CANCER |
| US9295731B2 (en) | 2013-04-01 | 2016-03-29 | Mark Quang Nguyen | Cleavable drug conjugates, compositions thereof and methods of use |
| KR102320190B1 (ko) | 2014-01-24 | 2021-11-03 | 에이아이 테라퓨틱스, 인코포레이티드 | 아필리모드 조성물 및 이를 사용하기 위한 방법 |
| RU2739992C2 (ru) | 2014-11-07 | 2020-12-30 | ЭйАй ТЕРАПЬЮТИКС, ИНК. | Композиции апилимода и способы их применения в лечении колоректального рака |
| CA2966359A1 (en) | 2014-11-07 | 2016-05-12 | Lam Therapeutics, Inc. | Apilimod for use in the treatment of renal cancer |
| WO2016126707A1 (en) | 2015-02-03 | 2016-08-11 | Lam Therapeutics, Inc. | Apilimod compositions and methods for using same |
| US20180078561A1 (en) | 2015-03-31 | 2018-03-22 | Lam Therapeutics, Inc. | Active metabolites of apilimod and uses thereof |
| TWI746449B (zh) | 2015-07-20 | 2021-11-21 | 美商Ａｉ治療公司 | 使用阿吡莫德治療癌症之方法 |
| EP3817736A4 (en) | 2018-07-05 | 2021-07-28 | Mayo Foundation for Medical Education and Research | PIKFYVE INHIBITORS |
| AR119934A1 (es) | 2019-09-12 | 2022-01-19 | Ai Therapeutics Inc | Inhibidores de pikfyve para terapia contra el cáncer |
-
2015
- 2015-01-23 KR KR1020167022474A patent/KR102320190B1/ko not_active Expired - Fee Related
- 2015-01-23 WO PCT/US2015/012733 patent/WO2015112888A1/en not_active Ceased
- 2015-01-23 MX MX2016009590A patent/MX373818B/es active IP Right Grant
- 2015-01-23 AU AU2015209133A patent/AU2015209133B2/en not_active Ceased
- 2015-01-23 JP JP2016548172A patent/JP6855243B2/ja not_active Expired - Fee Related
- 2015-01-23 RU RU2019107011A patent/RU2019107011A/ru unknown
- 2015-01-23 EP EP15740043.3A patent/EP3096757B1/en active Active
- 2015-01-23 CN CN201580016018.3A patent/CN106659716B/zh not_active Expired - Fee Related
- 2015-01-23 RU RU2016134406A patent/RU2016134406A/ru not_active Application Discontinuation
- 2015-01-23 US US15/113,154 patent/US10179135B2/en active Active
- 2015-01-23 CA CA2937655A patent/CA2937655C/en active Active
- 2015-01-23 BR BR112016017112A patent/BR112016017112A2/pt not_active Application Discontinuation
-
2016
- 2016-07-21 IL IL246879A patent/IL246879B/en active IP Right Grant
-
2018
- 2018-11-16 US US16/193,045 patent/US20190183902A1/en not_active Abandoned
-
2019
- 2019-12-27 US US16/728,566 patent/US11266654B2/en not_active Expired - Fee Related
-
2020
- 2020-12-04 JP JP2020201440A patent/JP2021046430A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017503842A5 (https=) | ||
| RU2019107011A (ru) | Композиции апилимода и способы их применения | |
| MX2024012131A (es) | Composicion farmaceutica, uso de la misma y metodo para tratar el cancer | |
| EP2562177A3 (en) | Transdermally deliverable buprenorphine prodrugs and abuse-resistant compositions thereof | |
| NZ604040A (en) | The use of inhibitors of bruton’s tyrosine kinase (btk) | |
| MY199967A (en) | Combinations of lsd1 inhibitors for use in the treatment of solid tumors | |
| WO2009001359A3 (en) | Compositions and methods for inhibiting expression of pro-apoptotic genes | |
| WO2015095819A3 (en) | Cancer treatment using combinations of erk and raf inhibitors | |
| WO2015097621A3 (en) | Pharmaceutical combinations | |
| JP2020505433A5 (https=) | ||
| SI2324008T1 (sl) | 3,4-diarilpirazoli kot protein-kinazni inhibitorji | |
| WO2006035434A3 (en) | Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases | |
| EA201201403A1 (ru) | Очень низкодозированные твердые пероральные лекарственные формы для гзт | |
| WO2018102687A3 (en) | Combination therapy for treating cancer | |
| WO2015095834A3 (en) | Cancer treatments using erk1/2 and bcl-2 family inhibitors | |
| MX2007006066A (es) | Inhibidores de jnk para el tratamiento de lesiones del snc. | |
| JP2016529285A5 (https=) | ||
| PH12018502422A1 (en) | Nanoliposomal irinotecan for use in treating small cell lung cancer | |
| JP2016515586A5 (https=) | ||
| JP2017516802A5 (https=) | ||
| JP2012502047A5 (https=) | ||
| JP2018503610A5 (https=) | ||
| WO2017042633A3 (en) | Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns | |
| MX2022011372A (es) | Composiciones de zinc-y-pga y metodos para tratar el cancer. | |
| WO2007123848A3 (en) | Therapeutic compositions containing modified class i slrp proteins |